Mu.Ta.Lig - COST ACTION CA15135

Dr. Bart ROMAN

14 June 2016


General information

Name: Bart
Surname: Roman
Cell phone number with international prefix: +32 472 467 140
Country: Belgium
Affiliation: Ghent University
Gender: F □ M
Year of the PhD title: 2012
Personal web page: and
Previous COST participation: No Yes


List of 10 selected publications within last 5 years

1. W. Debrouwer, T.S.A. Heugebaert, B.I. Roman, C.V. Stevens, Homogeneous Gold-Catalyzed Cyclization Reactions of Alkynes with N- and S-Nucleophiles, Adv. Synth. Catal., 2015, 14-15, 2975-3006 (doi: 10.1002/adsc.201500520)
2. I. Wauters, H. Goossens, E. Delbeke, K. Muylaert, B.I. Roman, K. Van Hecke, V. Van Speybroeck, C.V. Stevens, Beyond the diketopiperazine family with alternatively bridged brevianamide F analogues, J. Org. Chem., 2015, 80, 8046–8054 (doi: 10.1021/acs.joc.5b01161)
3. B.I. Roman, T. De Ryck, A. Patronov, S.H. Slavov, B.W.A. Vanhoecke, A.R. Katritzky, M.E. Bracke, C.V. Stevens, 4-Fluoro-3′,4′,5′-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model, Eur. J. Med. Chem., 2015, 627-639 (doi:10.1016/j.ejmech.2015.06.029)
4. E.I.P. Delbeke, B.I. Roman, G.B. Marin, K.M. Van Geem, C.V. Stevens, A new class of antimicrobial biosurfactants: quaternary ammonium sophorolipids, Green Chem., 2015, 17, 3373-3377 (doi: 10.1039/c5gc00120j)
5. M.E. Bracke, B.I. Roman, C.V. Stevens, L.M. Mus, V.S. Parmar, O. De Wever, Chick heart invasion assay for testing the invasiveness of cancer cells and the activity of potentially anti-invasive compounds, J. Vis. Exp., 2015, 100, e52792 (doi: 10.3791/52792
6. B.I. Roman, J.-C. Monbaliu, L.M. De Coen, S. Verhasselt, B. Schuddinck, E. Van Hoeylandt, C.V. Stevens, Feruloyl Benzotriazole and Weinreb Amide as Bioinspired Building Blocks: a Reactivity Study towards O-, N-, S- and C-Nucleophiles, Eur. J. Org. Chem., 2014, 2594-2611 (doi: 10.1002/ejoc.201301895)
7. B.I. Roman, L.M. De Coen, S.T.F.C. Mortier, T. De Ryck, B.W.A. Vanhoecke, A.R. Katritzky, M.E. Bracke, C.V. Stevens, Design, synthesis and structure–activity relationships of some novel, highly potent anti-invasive (E)- and (Z)-stilbenes, Bioorg. Med. Chem., 2013, 21, 5054-5063 (doi:10.1016/j.bmc.2013.06.048)
8. B.I. Roman, T.S.A. Heugebaert, M. Bracke, C.V. Stevens, Assessment of the Antineoplastic Potential of Chalcones in Animal Models, Curr. Med. Chem., 2013, 20, 186-221 (doi: 10.2174/0929867311320020003)
9. T.S.A. Heugebaert, B.I. Roman, C.V. Stevens, Synthesis of Isoindoles and Related Iso-condensed Heteroaromatic Pyrroles, Chem. Soc. Rev., 2012, 41, 5626-5640 (doi: 10.1039/C2CS35093A)
10. B.I. Roman, T. De Ryck, L. Dierickx, B.W.A. Vanhoecke, A.R. Katritzky, M. Bracke, C.V. Stevens, Exploration of the SAR of anti-invasive chalcones: Synthesis and biological evaluation of conformationally restricted analogues, Bioorg. Med. Chem., 2012, 20, 4812-4819 (doi: 10.1016/j.bmc.2012.05.069)


Main skills and expertise (up to 5)

1. organic synthesis
2. medicinal chemistry
3. preclinical development (in vitro, in vivo: pharmacology, DMPK)
4. oncology: invasion and metastasis


Main equipment/facilities available in the participants’ lab (up to 5)

1. all organic synthesis equipment
2. NMR
3. flow chemistry platform
4. in vitro assays for oncology
5. product library


Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

First of all, we can participate in the development of new chemical entities. We design and synthesize numerous compounds every year. These can be used in in silico or in vitro screens against a variety of targets.


We also have an in-house compound collection which can be offered for screening (for most compounds at least one target has already been defined from the onset of the project, though we also have a program on phenotypic screening, thus without readout of a specific molecular target).


We can also help in the selection of cancer-related targets and bring the Action in contact with laboratories (with whom we collaborate intimately) that offer screening against cancer-related targets.


I am also eager to further develop the capabilities of our laboratory in in silico screening by coming into contact with specialists through the Action.


I am also very interested in co-authoring the book on multi-targeted drugs.


Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data 2
WG3: Development of chemical databases 4
WG4: Development of Computational methods for multiple ligand design and discovery 3